Figure 2. c-IAP2 compensates for c-IAP1^H582A in non-canonical NF-κB inhibitory- and TNFR1 complexes.

(A) Expression of p100 and p52 in MEFs was detected by immunoblotting. (B and F) MEFs were untreated (−) or transfected with non-targeting control (ctr) or c-IAP2 siRNA (c2) for 24 hr and lysed. p52 and c-IAP1/2 levels were determined by immunoblotting. IκBα expression was analyzed by immunoblotting of lysates of MEFs treated for the indicated times with 1 ng/ml of TNFα (C) or 15′ with the indicated doses of TNFα (D). (F) MEFs were untreated (-) or transfected with non-targeting control (ctr) or c-IAP2 siRNA for 24 hr, then treated with 1 ng/ml TNFα for 15′ and lysed. IκBα expression was analyzed by immunoblotting. Lanes were rearranged for clarity.